Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Share-based Compensation (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Share-based Compensation for 11 consecutive years, with $111540.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 120.68% to $111540.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $537684.0 through Dec 2025, up 118.61% year-over-year, with the annual reading at $537540.0 for FY2025, 118.63% up from the prior year.
  • Share-based Compensation for Q4 2025 was $111540.0 at Marker Therapeutics, up from $33000.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $1.7 million in Q2 2021, with the low at -$1.3 million in Q4 2022.
  • Average Share-based Compensation over 5 years is $618148.5, with a median of $492572.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation crashed 190.14% in 2022, then surged 377.41% in 2025.
  • Over 5 years, Share-based Compensation stood at $1.5 million in 2021, then plummeted by 190.14% to -$1.3 million in 2022, then surged by 165.65% to $868101.0 in 2023, then tumbled by 94.18% to $50544.0 in 2024, then surged by 120.68% to $111540.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $111540.0, $33000.0, and $14000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.